- Home
- PHUN vs ONCY Comparison
PHUN vs ONCY Comparison
Compare PHUN & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- ONCY
- Stock Information
- Founded
- PHUN 2009
- ONCY 1998
- Country
- PHUN United States
- ONCY Canada
- Employees
- PHUN N/A
- ONCY N/A
- Industry
- PHUN EDP Services
- ONCY Pharmaceuticals and Biotechnology
- Sector
- PHUN Technology
- ONCY Health Care
- Exchange
- PHUN Nasdaq
- ONCY Nasdaq
- Market Cap
- PHUN 58.3M
- ONCY 49.1M
- IPO Year
- PHUN N/A
- ONCY 1999
- Fundamental
- Price
- PHUN $3.13
- ONCY $0.47
- Analyst Decision
- PHUN Buy
- ONCY Strong Buy
- Analyst Count
- PHUN 2
- ONCY 3
- Target Price
- PHUN $7.50
- ONCY $4.33
- AVG Volume (30 Days)
- PHUN 185.6K
- ONCY 285.0K
- Earning Date
- PHUN 05-12-2025
- ONCY 05-14-2025
- Dividend Yield
- PHUN N/A
- ONCY N/A
- EPS Growth
- PHUN N/A
- ONCY N/A
- EPS
- PHUN N/A
- ONCY N/A
- Revenue
- PHUN $2,956,000.00
- ONCY N/A
- Revenue This Year
- PHUN $10.47
- ONCY N/A
- Revenue Next Year
- PHUN $55.58
- ONCY N/A
- P/E Ratio
- PHUN N/A
- ONCY N/A
- Revenue Growth
- PHUN N/A
- ONCY N/A
- 52 Week Low
- PHUN $2.22
- ONCY $0.47
- 52 Week High
- PHUN $14.60
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- PHUN 59.04
- ONCY 34.39
- Support Level
- PHUN $2.97
- ONCY $0.54
- Resistance Level
- PHUN $3.19
- ONCY $0.65
- Average True Range (ATR)
- PHUN 0.13
- ONCY 0.03
- MACD
- PHUN 0.03
- ONCY -0.00
- Stochastic Oscillator
- PHUN 84.33
- ONCY 11.38
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.